Skip Navigation


Carcinogenesis Advance Access originally published online on December 13, 2005
Carcinogenesis 2006 27(3):361-373; doi:10.1093/carcin/bgi310
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/3/361    most recent
bgi310v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Knowles, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knowles, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

REVIEW

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

Margaret A. Knowles *

Cancer Research UK Clinical Centre, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK

* To whom correspondence should be addressed. Tel: +44 1132064913; Fax: +44 1132429886; Email: margaret.knowles{at}cancer.org.uk

Cancer of the bladder shows divergent clinical behaviour following diagnosis and it has been proposed that two major groups of tumours exist that develop via different molecular pathways. Low-grade, non-invasive papillary tumours recur frequently, but patients with these tumours do not often suffer progression of disease to muscle invasion. In contrast, tumours that are invading muscle at diagnosis are aggressive and associated with significant mortality. Molecular studies have identified distinct genetic, epigenetic and expression changes in these groups. However, it is not yet clear whether there is direct progression of low-grade superficial tumours to become invasive (a Jeckell and Hyde scenario) or whether in those patients who apparently progress from one form of the disease to the other, different tumour clones are involved and that the two tumour groups are mutually exclusive (‘chalk and cheese’). If the latter is true, then attempts to identify molecular markers to predict progression of low-grade superficial bladder tumours may be fruitless. Similarly, it is not clear whether other subgroups of tumours exist that arise via different molecular pathways. There is now a large amount of molecular information about bladder cancer that facilitates examination of these possibilities. Some recent studies provide evidence for the existence of at least one further group of tumours, high-grade superficial papillary tumours, which may develop via a distinct molecular pathway. Patients with such tumours do show increased risk of disease progression and for these there may exist a real progression continuum from non-invasive to invasive. If this is the case, definition of the molecular signature of this pathway and improved understanding of the biological consequences of the events involved will be pivotal in disease management.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. Kawanishi, Y. Matsui, M. Ito, J. Watanabe, T. Takahashi, K. Nishizawa, H. Nishiyama, T. Kamoto, Y. Mikami, Y. Tanaka, et al.
Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2579 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Schwarz, M Rechenmacher, T Filbeck, R Knuechel, H Blaszyk, A Hartmann, and G Brockhoff
Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions
J. Clin. Pathol., March 1, 2008; 61(3): 272 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Lee, J. Jeong, T. Majewski, S. E. Scherer, M.-S. Kim, T. Tuziak, K. S. Tang, K. Baggerly, H. B. Grossman, J.-H. Zhou, et al.
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia
PNAS, August 21, 2007; 104(34): 13732 - 13737.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. P. Mitra, R. H. Datar, and R. J. Cote
Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification
J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
X. D. Zhou, M. A. Sens, S. H. Garrett, S. Somji, S. Park, V. Gurel, and D. A. Sens
Enhanced Expression of Metallothionein Isoform 3 Protein in Tumor Heterotransplants Derived from As+3- and Cd+2-Transformed Human Urothelial Cells
Toxicol. Sci., October 1, 2006; 93(2): 322 - 330.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Hernandez, E. Lopez-Knowles, J. Lloreta, M. Kogevinas, A. Amoros, A. Tardon, A. Carrato, C. Serra, N. Malats, and F. X. Real
Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas
J. Clin. Oncol., August 1, 2006; 24(22): 3664 - 3671.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Lopez-Knowles, S. Hernandez, N. Malats, M. Kogevinas, J. Lloreta, A. Carrato, A. Tardon, C. Serra, F. X. Real, and EPICURO Study Group Investigators
PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors.
Cancer Res., August 1, 2006; 66(15): 7401 - 7404.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.